|
Type |
Offentliggørelse |
58 |
Journal |
Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161. |
201 |
Journal |
Thompson DF, Allen LV, Stiles ML. Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2530-2531. |
226 |
Journal |
Walker SE, DeAngelis C, Iazzetta J. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm 1991 ; 44: 289-295. |
266 |
Journal |
Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
300 |
Journal |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
301 |
Journal |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
349 |
Journal |
Nahata MC, Hipple TF, Strausbaugh SD. Stability of phenobarbital sodium diluted in 0.9% sodium chloride injection. Am J Hosp Pharm 1986 ; 43: 384-385. |
642 |
Journal |
Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA. Norepinephrine stability in saline solutions. Hosp Pharm 1988 ; 23: 44,49, 59. |
660 |
Journal |
Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232. |
921 |
Journal |
Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. |
1057 |
Journal |
Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207. |
1072 |
Journal |
Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459. |
1412 |
Journal |
Brett A, Riggs RM, Webster AA, Benner KW. Y-site stability of fosphenytoin and sodium phenobarbital. Int J Pharm Compound 1999 ; 3: 64-66. |
1415 |
Journal |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74. |
1625 |
Journal |
Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. |
1802 |
Journal |
Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194. |
1925 |
Journal |
Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519. |
1974 |
Journal |
Chandler SW, Trissel LA, Weinstein SM Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171. |
2090 |
Journal |
Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196. |
2262 |
Journal |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
3379 |
Journal |
Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524. |
3408 |
Journal |
Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21. |
3501 |
Laboratorium |
Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics Pfizer 2011 |
3525 |
Laboratorium |
Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012 |
3526 |
Laboratorium |
Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010 |
3531 |
Laboratorium |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014 |
3596 |
Laboratorium |
Chlorpromazine (Largactil®) - Summary of Product Characteristics Sanofi 2014 |
3631 |
Laboratorium |
Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit Aguettant 2016 |
3674 |
Laboratorium |
Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016 |
3676 |
Laboratorium |
Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit Hospira 2014 |
4009 |
Laboratorium |
Droperidol - Résumé des Caractéristiques du Produit Panpharma 2017 |
4419 |
Journal |
Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161. |
4435 |
Journal |
Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27. |
4543 |
Journal |
Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295. |
4700 |
Laboratorium |
Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics AS Kalceks 2022 |
4742 |
Journal |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255. |